February 2026 Paying to Cut the Line at FDA Is Still a Thing; A Look at PRVs and Their Value View research note
December 2025 Upcoming VEGFA/PD-(L)1 Catalysts – Next 3-4 Months Could Be a Wild Ride View research note
November 2025 Biopharma / ACR 2025 Takeaways: Cell Therapy and T-cell Engager Excitement Grows View research note
October 2025 STAT6 of the Union: Competitive Landscape of STAT6-Targeting Therapies View research note